Fc-Engager Platform: Antigen-Specific Immune Tolerance

LoopLab Bio is developing a proprietary Fc-Engager platform, a new class of biologics designed to establish antigen-specific immune tolerance. By selectively engaging the inhibitory receptor CD32B together with disease-related antigens, our approach seeks to retrain the immune system rather than broadly suppress it.

Key features of the platform

• Designed to promote durable tolerance and long-term disease management

• Modular “plug-and-play” design, adaptable across multiple indications

• Supported by validation in in vitro, ex vivo, and in vivo humanized models

• Compatible with scalable CHO cell production for future clinical use

Exploratory pipeline programs (early preclinical stage):

• Autoimmune & allergy: Celiac disease (gliadin), bullous pemphigoid (BP180), house dust mite allergy (Derp1/2)

• Rare metabolic / ADA prevention: Pompe (ERT adjunct, Lumizyme), Fabry (ERT adjunct, Fabrazyme), Pegloticase (ADA prevention in gout)

• Transplantation: Imlifidase-FcE adjunct concepts to help address antibody rebound and re-dosing challenges

These programs are currently at the exploratory and validation stages, and serve to illustrate the broad potential of the Fc-Engager platform.

We warmly welcome opportunities to explore co-development, licensing, or translational collaborations with partners who share our vision of advancing safe and durable immune tolerance therapies for patients worldwide.